Strategic Overhaul: Bioretec's strategy for 2026-2028 focuses on commercial performance and sales acceleration in both the U.S. and international markets, aiming for growth through ongoing R&D and expansion of the RemeOs™ product family.
Innovation-Driven: The company is committed to establishing a competitive advantage through leading materials science and clinical evidence generation, with the goal of becoming a recognized player in the global orthopedic market, particularly in absorbable metal implants by the end of the strategy period.
Financial Targets: Despite planned strategic investments in R&D and commercialization, Bioretec does not expect to achieve cash flow positivity or profitability during this period, indicating a focus on long-term growth.
Pipeline Update: Bioretec plans to introduce a new product every 12-18 months, particularly expanding the RemeOs™ product family to meet market demand for high-performance absorbable implants, further solidifying its market position.
BRT
$15.03+Infinity%1D
Analyst Views on BRT
Wall Street analysts forecast BRT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRT is 18.50 USD with a low forecast of 16.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast BRT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRT is 18.50 USD with a low forecast of 16.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 15.060
Low
16.00
Averages
18.50
High
20.00
Current: 15.060
Low
16.00
Averages
18.50
High
20.00
Citizens JMP
Outperform
downgrade
$24 -> $20
2025-11-18
Reason
Citizens JMP
Price Target
$24 -> $20
2025-11-18
downgrade
Outperform
Reason
Citizens JMP lowered the firm's price target on BRT Apartments to $20 from $24 and keeps an Outperform rating on the shares following the Q3 print. The firm expects fundamentals to provide a favorable backdrop next year, and thinks additional capital could be accessed through debt refinancing in the future to unlock opportunities for value creation, the analyst tells investors in a research note.
B. Riley
Buy
maintain
$21
2025-10-01
Reason
B. Riley
Price Target
$21
2025-10-01
maintain
Buy
Reason
B. Riley raised the firm's price target on BRT Apartments to $21 from $19.50 and keeps a Buy rating on the shares. The firm sees the company benefitting from the lower interest rate environment. BRT offers "compelling value" at current share levels despite its small cap size and limited trading volume, the analyst tells investors in a research note.
B. Riley Securities
John Massocca
Strong Buy
Maintains
$22 → $21
2025-03-27
Reason
B. Riley Securities
John Massocca
Price Target
$22 → $21
2025-03-27
Maintains
Strong Buy
Reason
B. Riley lowered the firm's price target on BRT Apartments to $21 from $22 and keeps a Buy rating on the shares. The company's Q4 results reflected the vulnerability of the Sunbelt apartment market, given continued new supply pressures and upward pressure on operating expenses, the analyst tells investors in a research note. However, the firm believes these headwinds are not enough to justify BRT's current valuation discount.
About BRT
BRT Apartments Corp. is a real estate investment trust that owns, operates, and to a lesser extent, holds interest in joint ventures that own and operate multifamily properties. The Company owns or has interests in over 31 multifamily properties with 8,311units in 11 states and has preferred equity investments in two multi-family properties. Generally, its multifamily properties are garden apartments and, to a lesser extent, mid-rise or town home style properties that provide residents with amenities, such as a clubhouse, swimming pool, laundry facilities and Internet access. In addition to its multifamily properties and preferred loan investments, the Company owns assets, and in particular, real estate assets. Its properties include Silvana Oaks Apartments, Avondale Station, Brixworth at Bridge Street, Newbridge Commons, Crossings of Bellevue, Avalon Apartments, Parkway Grande, Woodland Trails, Grove at River Place, Kilburn Crossing, The Woodland Apartments, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
